United States-based political advisory and lobbying firm, Von Batten-Montague-York, says the US District Court for the District of Columbia has officially accepted and docketed its Motion for Leave to File Brief Amicus Curiae and Supplemental Notice of Evidentiary Exhibits in the ongoing drug trafficking case linked to Nigeria’s President Bola Tinubu.
Von Batten-Montague-York made this disclosure in a statement posted on its verified X handle.
The firm said its submissions are now officially part of the docket and before the Court for consideration, regardless of whether President Tinubu opposes them.
According to the firm, it is a major victory for the American and Nigerian people, noting that its objective was to ensure that the Court is fully aware that the Nigerian Presidency and senior Nigerian officials have publicly discussed the case while President Tinubu was simultaneously seeking privacy protection before the Court.
“We are happy to announce that our Motion for Leave to File Brief Amicus Curiae and Supplemental Notice of Evidentiary Exhibits have been officially accepted and docketed with the United States District Court for the District of Columbia.
“Both submissions have now been officially entered on the federal docket in Greenspan v. Executive Office for U.S. Attorneys et al., Case No. 1:23-cv-01816-BAH. We thank President Tinubu, his advisers, and his ministers for refusing to stop digging themselves into a hole.
“You cannot demand privacy in a U.S. federal court while publicly litigating the same controversy and attacking those advocating for disclosure.
“We are very pleased with this outcome because, regardless of whether the Court ultimately grants or denies our Motion for Leave, our submissions are now on the docket, and the Court has before it evidence concerning public statements by President Tinubu’s officials and relatives about the underlying controversy, as well as their public mischaracterisations of facts relating to the case,” the firm tweeted.
Tinubu hit with more trouble as US court accepts new evidence in alleged drug case